Therapeutic gene transfer for rheumatoid arthritis

Reumatismo

Volumn 56, Issue 1 SUPPL. 1, 2004, Pages 51-61

  Boissier, Marie Christophe ^a,b   Bessis, N ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Cytokines; Gene therapy; Inflammation; Rheumatoid arthritis

Indexed keywords

ADENOVIRUS VECTOR; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; PLASMID VECTOR; RETROVIRUS VECTOR; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

CYTOKINE PRODUCTION; GENE TRANSFER; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; FORECASTING; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS;

EID: 2342640850     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Kavanaugh AF LP. Rheumatoid arthritis. Third edition ed: Gallin JI, Snyderman R (eds). Lippincott Williams and Wilkins, 1999.
2. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
3. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
4. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996; 39: 1092-101.
5. Song XY, Gu M, Jin WW, Klinman DM, Wahl SM. Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest 1998; 101: 2615-21.
6. Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledda MF, Podhajcer OL. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther 1997; 4: 553-9.
7. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999; 42: 90.
8. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C. Adenovirus mediated transfer of viral IL-10 gene inhibits collagen-induced arthritis. J. Immunol 1998; 160: 5213-20.
9. Watanabe S, Imagawa T, Boivin GP, Gao G, Wilson JM, Hirsch R. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Mol Ther 2000; 2: 147-52.
10. Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC, et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999; 162: 3625-32.
11. Lechman ER, Jaffurs D, Ghivizzani SC, Gambotto A, Kovesdi I, Mi Z, et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 1999; 163: 2202-8.
12. Ma Y, Thornton S, Duwel LE, Boivin GP, Giannini EH, Leiden JM, et al. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol 1998; 161: 1516-24.
13. Miyata M, Sasajima T, Sato H, Saito A, Iriswa A, Sato Y, et al. Suppression of collagen induced arthritis in mice utilizing plasmid DNA encoding interleukin 10. J Rheumatol 2000; 27: 1601-5.
14. Setoguchi K, Misaki Y, Araki Y, Fujio K, Kawahata K, Kitamura T, et al. Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. J Immunol 2000; 165: 5980-6.
15. Quattrocchi E, Dallman MJ, Dhillon AP, Quaglia A, Bagnato G, Feldmann M. Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver. J Immunol 2001; 166: 5970-8.
16. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996; 156: 3558-62.
17. Oligino T, Ghivizzani S, Wolfe D, Lechman E, Krisky D, Mi Z, et al. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther 1999; 6: 1713-20.
18. Hung GL, Galea-Lauri J, Mueller GM, Georgescu HI, Larkin LA, Suchanek MK, et al. Suppression of intraarticular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther 1994; 1: 64-9.
19. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS, Jr., et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996; 93: 402-6.
20. Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993; 90: 10764-8.
21. Bakker AC, Joosten LA, Arntz OJ, Helsen, MM, Bendele AM, van de Loo FA, van den Berg WB. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893-900.
22. Roessler BJ, Hartman JW, Vallance DK, Latta JM, Janich SL, Davidson BL. Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum Gene Ther 1995; 6: 307-16.
23. Kim SH, Evans CH, Kim S, Oligino T, Ghivizzani SC, Robbins PD. Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res 2000; 2: 293-302.
24. Zhang HG, Xie J, Yang P, Wang Y, Xu L, Liu D, et al. Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther 2000; 11: 2431-42.
25. Chernajovsky Y, Adams G, Podhajcer OL, Mueller GM, Robbins PD, Feldmann M. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. Gene Ther 1995; 2: 731-5.
26. Quattrocchi E, Walmsley M, Browne K, Williams RO, Marinova-Mutafchieva L, Buurman W, et al. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J Immunol 1999; 163: 1000-9.
27. Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci USA 1994; 91: 215-9.
28. Le CH, Nicolson AG, Morales A, Sewell KL. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene. Arthritis Rheum 1997; 40: 1662-9.
29. Ghivizzani SC, Lechman ER, Kang R, Tio C, Kolls J, Evans CH, et al. Direct adenovirus-mediated gene transfer of interleukin-1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc. Natl. Acad. Sci. USA. 1998; 95: 4613-8.
30. Lubberts E, Joosten LA, van Den Bersselaar L, Helsen MM, Bakker AC, van Meurs JB, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999; 163: 4546-56.
31. Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, Amin MA, et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 2001; 166: 1214-22.
32. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000; 105: 1697-710.
33. Boyle DL, Nguyen KH, Zhuang S, Shi Y, McCormack JE, Chada S, et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2activity. Gene Ther. 1999; 6: 1911-8.
34. Cottard V, Mulleman D, Bouille P, Mezzina M, Boissier MC, Bessis N. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther 7: 1930-9; 2000.
35. Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275-84.
36. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166: 3499-505.
37. Bessis N, Honiger J, Damotte D, Minty A, Fournier C, Fradelizi D, et al. Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA). Clin Exp Immunol 1999; 117: 376-82.
38. Bessis N, Chiocchia G, Kollias G, Minty A, Fournier C, Fradelizi D, et al. Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol 1998; 111: 391-6.
39. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996; 26: 2399-403.
40. Bessis N, Guery L, Mantovani A, Vecchi A, Sims JE, Fradelizi D, et al. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur J Immunol 2000; 30: 867-75.
41. Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997; 100: 1951-7.
42. Okamoto K, Asahara H, Kobayashi T, Matsuno H, Hasunuma T, Kobata T, et al. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther 1998; 5: 331-8.
43. Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito H, Hirokawa K, et al. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 2000; 165: 7246-52.
44. Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999; 5: 760-7.
45. Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennett BL, et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897-907.
46. Goossens PH, Schouten GJ, 't Hart B, Bout A, Brok HP, Kluin PM, et al. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys. Hum Gene Ther 1999; 10: 1139-49.
47. Boissier M-C. Elements de réflexion sur le principe de précaution. Rev Rhum 2003; In Press.
48. Bessis N, Doucet C, Cottard V, Douar A-M, Firat H, Jorgensen C, et al. Gene therapy in rheumatoid arthritis. J Gene Med 2002; 4: 581-9.
49. Ghivizzani SC, Oligino TJ, Glorioso JC, Robbins PD, Evans CH. Gene therapy approaches for treating rheumatoid arthritis. Clin Orthop (379 Suppl): 2000; S288-99.
50. Saidenberg-Kermanach N, Bessis N, Deleuze V, Bureau M, Scherman D, Boissier M-C. Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med 2003; 5: 164-71.
51. Ghivizzani SC, Lechman ER, Tio C, Mule KM, Chada S, McCormack JE, et al. Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. Gene Ther 1997; 4: 977-82.
52. Makarov SS, Olsen JC, Johnston WN, Schwab JH, Anderle SK, Brown RR, et al. Retrovirus mediated in vivo gene transfer to synovium in bacterial cell wall-induced arthritis in rats. Gene Ther 1995; 2: 424-8.
53. Pap T, Gay RE, Gay S. Gene transfer: from concept to therapy. Curr Opin Rheumatol 2000; 12: 205-10.
54. Evans CH, Ghivizzani SC, Smith P, Shuler FD, Mi Z, Robbins PD. Using gene therapy to protect and restore cartilage. Clin Orthop (379 Suppl): 2000; S214-9.
55. Gouze E, Ghivizzani SC, Palmer GD, Gouze JN, Robbins PD, Evans CH. Gene therapy for rheumatoid arthritis. Expert Opin Biol Ther 2001; 1: 971-8.
56. Wickham TJ. Targeting adenovirus. Gene Ther 2000; 7: 110-4.
57. Evans CH, Ghivizzani SC, Oligino TA, Robbins PD. Future of adenoviruses in the gene therapy of arthritis. Arthritis Res 2001; 3: 142-6.
58. Sawchuk SJ, Boivin GP, Duwel LE, Ball W, Bove K, Trapnell B, et al. Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. Hum Gene Ther 1996; 7: 499-506.
59. Jomary C, Vincent KA, Grist J, Neal MJ, Jones SE. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther 1997; 4: 683-90.
60. Haberman RP, McCown TJ, Samulski RJ. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 1998; 5: 1604-11.
61. Zhang L, Wang D, Fischer H, Fan PD, Widdicombe JH, Kan YW, et al. Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. Proc Natl Acad Sci USA 1998; 95: 10158-63.
62. Pan RY, Xiao X, Chen SL, Li J, Lin LC, Wang HJ, et al. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. J Virol 1999; 73: 3410-7.
63. Goater J, Muller R, Kollias G, Firestein GS, Sanz I, O'Keefe RJ, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol 2000; 27: 983-9.
64. Arai Y, Kubo T, Fushiki S, Mazda O, Nakai H, Iwaki Y, et al. Gene delivery to human chondrocytes by an adeno associated virus vector. J Rheumatol 2000; 27: 979-82.
65. Pan RY, Chen SL, Xiao X, Liu DW, Peng HJ, Tsao YP. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43: 289-97.
66. Zhang HG, Huang N, Liu D, Bilbao L, Zhang X, Yang P, et al. Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts. Arthritis Rheum 2000; 43: 1094-105.
67. Manning WC, Zhou S, Bland MP, Escobedo JA, Dwarki V. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 1998; 9: 477-85.
68. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72: 9795-805.
69. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225-7.
70. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261: 1328-30.
71. Durie FH, Foy TM, Noelle RJ. The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease. Res Immunol 145(3): 200-5; discussion 1994; 244-9.
72. Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002; 69: 123-32.
73. Boissier MC, Bessis N, Falgarone G. Options for blocking interleukin-1 in rheumatoid arthritis. Joint Bone Spine 2002; 4: 351-.
74. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261: 472-5.
75. Burger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995; 96: 38-41.
76. Trippel SB. Growth factor actions on articular cartilage. J Rheumatol Suppl 1995; 43: 129-32.
77. Kobayashi T, Okamoto K, Kobata T, Hasunuma T, Kato T, Hamada H, et al. Novel gene therapy for rheumatoid arthritis by FADD gene transfer: induction of apoptosis of rheumatoid synoviocytes but not chondrocytes. Gene Ther 2000; 7: 527-33.
78. Bessis N, Cottard V, Saidenberg-Kermanach' N, Lemeiter D, Fournier C, Boissier MC. Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis. J Gene Med 2002; 4: 300-7.
79. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-80.
80. Bakker A, van de Loo FAJ, Bennink M, Joosten LAB, Varley AW, et al. Inflammation-inducible intra-articular production of human IL-1 receptor antagonist results in a more efficient inhibition of collagen-induced arthritis than does constitutive expression of the same transgene. Arthritis res 3 suppl 1: A2; 2001.